Cancer immunotherapy via stem cell-derived NK cells.

NK cells are the first sentinels of the immune system that can recognize and eradicate transformed cells. Their activation without a need for additional signaling have attracted great attention on the use of NK cells as a promising option in cancer immunotherapy. However, the large-scale production of NK cells for successful NK cells therapy is a challenge that needs to be tackled. Engineering NK cells to avoid tumor escape and improve their antitumor potency are the other matters of focus that have widely been studied in the recent years. This paper reviews the most recent advances in the stem cell-derived NK cell technology and discusses the potential of the engineered NK cells for clinical applications in cancer immunotherapy.

[1]  Feifei Li,et al.  Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer , 2022, Frontiers in Immunology.

[2]  Huajun Zhang,et al.  Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell‐derived induced pluripotent stem cell library , 2022, FEBS open bio.

[3]  D. Raulet,et al.  Roles of natural killer cells in immunity to cancer, and applications to immunotherapy , 2022, Nature Reviews Immunology.

[4]  James Brown,et al.  Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy , 2022, Cancers.

[5]  J. Sunwoo,et al.  Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells , 2022, Journal for ImmunoTherapy of Cancer.

[6]  M. Akbari,et al.  Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy , 2022, Molecular cancer.

[7]  Xueqing Yu,et al.  Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors , 2021, International journal of molecular sciences.

[8]  M. Kuo,et al.  An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells , 2021, Biomedicines.

[9]  K. Rezvani,et al.  Engineering the next generation of CAR-NK immunotherapies , 2021, International Journal of Hematology.

[10]  Peter Karagiannis,et al.  iPSC-Derived Natural Killer Cells for Cancer Immunotherapy , 2021, Molecules and cells.

[11]  Cai Zhang,et al.  Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy , 2021, Cellular & Molecular Immunology.

[12]  R. Gottardi,et al.  Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies , 2021, Cancers.

[13]  Z. Shao,et al.  Natural killer cells in cancer biology and therapy , 2020, Molecular Cancer.

[14]  Krishanu Saha,et al.  Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies , 2020, Stem Cell Research & Therapy.

[15]  W. Wels,et al.  Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity , 2020, Cells.

[16]  É. Vivier,et al.  SnapShot: Natural Killer Cells , 2020, Cell.

[17]  Seong-Jin Kim,et al.  NK Cell-Based Immunotherapies in Cancer , 2020, Immune network.

[18]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[19]  João Nuno Moreira,et al.  Current challenges and emerging opportunities of CAR-T cell therapies. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[20]  T. Klingebiel,et al.  The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation , 2019, Front. Immunol..

[21]  F. Locatelli,et al.  NK Cell-Based Immunotherapy for Hematological Malignancies , 2019, Journal of clinical medicine.

[22]  K. Rezvani.  Adoptive cell therapy using engineered natural killer cells , 2019, Bone Marrow Transplantation.

[23]  Jia Liu,et al.  Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges. , 2019, International immunopharmacology.

[24]  H. Farin,et al.  3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids , 2019, The EMBO journal.

[25]  Diana Crow.  Could iPSCs Enable “Off-the-Shelf” Cell Therapy? , 2019, Cell.

[26]  Q. Rao,et al.  2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies , 2019, Journal of Hematology & Oncology.

[27]  D. Maloney,et al.  Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy , 2019, Expert review of hematology.

[28]  A. Skubitz,et al.  Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. , 2019, Gynecologic oncology.

[29]  J. Luke,et al.  Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies , 2019, Journal of Immunotherapy for Cancer.

[30]  Y. Diao,et al.  Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy , 2019, International journal of molecular sciences.

[31]  S. Matosevic,et al.  Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells , 2018, Journal of Immunotherapy for Cancer.

[32]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[33]  S. Matosevic,et al.  Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells , 2018, Front. Immunol..

[34]  Tyler J. Reich,et al.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell , 2018, Nature Medicine.

[35]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[36]  K. Beaman,et al.  Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells. , 2018, Experimental hematology.

[37]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[38]  Seung Woo Park,et al.  In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model , 2018, In Vivo.

[39]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[40]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[41]  D. Kaufman,et al.  Concise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy , 2018, Stem cells.

[42]  Katayoun Rezvani,et al.  Engineering Natural Killer Cells for Cancer Immunotherapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  C. Buchholz,et al.  Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts , 2017, EMBO molecular medicine.

[44]  S. Viswanathan,et al.  A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. , 2017, Oncotarget.

[45]  W. Wels,et al.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity , 2017, Front. Immunol..

[46]  U. Hegde,et al.  Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies , 2017, Cancer Immunology, Immunotherapy.

[47]  L. Müller,et al.  Type I Interferons and Natural Killer Cell Regulation in Cancer , 2017, Front. Immunol..

[48]  J. Madrigal,et al.  Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications , 2017, Front. Immunol..

[49]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[50]  E. Yvon,et al.  Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. , 2016, Cytotherapy.

[51]  A. Bertoletti,et al.  CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes , 2016, Scientific Reports.

[52]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[53]  R. Handgretinger,et al.  Exploitation of natural killer cells for the treatment of acute leukemia. , 2016, Blood.

[54]  J. Trapani,et al.  A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer , 2016, Oncotarget.

[55]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[56]  A. Lundqvist,et al.  Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience , 2016, Human vaccines & immunotherapeutics.

[57]  D. Kaufman,et al.  Induced Pluripotent Stem Cell‐Derived Natural Killer Cells for Treatment of Ovarian Cancer , 2016, Stem cells.

[58]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[59]  E. Alici,et al.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity , 2015, Front. Immunol..

[60]  Haiqin Ren,et al.  Multiple effects of IL-21 on human NK cells in ex vivo expansion. , 2015, Immunobiology.

[61]  A. Jauch,et al.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  L. Moretta,et al.  Effect of tumor cells and tumor microenvironment on NK‐cell function , 2014, European journal of immunology.

[63]  D. Kaufman,et al.  Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo , 2014, Stem cells.

[64]  M. Smyth,et al.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors , 2013, Proceedings of the National Academy of Sciences.

[65]  H. Vié,et al.  The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential , 2013, mAbs.

[66]  D. Kaufman,et al.  Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy , 2013, Stem cells translational medicine.

[67]  Sumati Rajagopalan,et al.  Controlling natural killer cell responses: integration of signals for activation and inhibition. , 2013, Annual review of immunology.

[68]  D. Campana,et al.  A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. , 2012, Cytotherapy.

[69]  S. Perez,et al.  New insights into the role of NK cells in cancer immunotherapy , 2012, Oncoimmunology.

[70]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[71]  F. Locatelli,et al.  Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? , 2012, Blood.

[72]  R. Solana,et al.  Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients , 2012, Immunology and cell biology.

[73]  Shijiang Lu,et al.  Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components , 2011, Stem cells international.

[74]  A. Gratwohl,et al.  Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. , 2010, Cytotherapy.

[75]  P. Woll,et al.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. , 2009, Blood.

[76]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[77]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[78]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[79]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[80]  N. Vujanović.  Role of TNF Family Ligands in Antitumor Activity of Natural Killer Cells , 2001, International reviews of immunology.

[81]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[82]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[83]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[84]  R. Vance,et al.  Regulation of the natural killer cell receptor repertoire. , 2001, Annual review of immunology.